According to the Epilepsy Foundation 1 in 26 people in the U.S.A will develop epilepsy at some point in their life, however, epilepsy is a very diverse condition which makes researching it especially challenging. In this blog, we will discuss the model organisms commonly used in epilepsy research, and how their characteristics act as advantages and limitations when modeling epilepsy.
Model organisms are essential to experimental research, allowing researchers and scientists to address a variety of questions. While no model is perfect, some models are more suitable for investigating specific questions than others. In this blog, we provide an overview of many commonly used model organisms, and compare their advantages and limitations.
We have found whole gene humanization can create a platform for highly translatable results in a model organism. Currently there is a big need for functional studies of Variants of Uncertain Significance (VUS).
Did you know C. elegans are an ideal model for disease modeling? It may seem unlikely that such a tiny animal would work well for modeling and studying human diseases, but we believe in their power and want you to as well, so we’ve outlined a few of their strengths so you can learn more about the benefits of using C. elegans for disease modeling.
With the advent of the molecular biology revolution and the human genome project in the 1990s there was a historic shift toward target-based drug development. Target-based drug development, or TDD, relies on prior knowledge of disease mechanisms and targets before development can begin.
We created over 90 point mutations in the STXBP1 gene via CRISPR. A map of these point mutations can be seen above. Clinical variants were selected from the ClinVar database, literature, the Gnomad database, clinical researchers, and the STXBP1 foundation.
Using zebrafish modeling in a rare human disease may be the perfect physiologic model to better understand the disease and generate more individualized therapeutic medical responses and positive outcomes for higher risk COVID-19 groups.